物质信息
ID:1079
名称和标识
商标名
NovantroneNovantronMitox
IUPAC标准名
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione
别名
MitoxanthroneMitoxantrone HClDHAQMitoxantrona [INN-Spanish]Mitoxantrone dihydrochlorideMitozantrone hydrochlorideDHADDHAQ HClDihydroxyanthraquinoneMitoxantronMitoxantrone 2HClMitoxantrone hydrochlorideMitoxantronum [INN-Latin]MitozantronemitoxantroneMitoxantrone
IUPAC传统名
mitoxantrone
化合物性质
理化性质
疏水性(logP)
-3.1
描述信息
Drug Groups
approved; investigational
Description
An anthracenedione-derived antineoplastic agent. [PubChem]
Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Pharmacology
Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
Toxicity
Severe leukopenia with infection.
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic
Absorption
Poorly absorbed following oral administration
Half Life
75 hours
Protein Binding
78%
Distribution
* 1000 L/m2
Clearance
* 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]
* 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
* 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]
* 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
* 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]
References
•
Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74.
[Pubmed]
External Links
分子图谱
暂无数据
点击上传数据
参考文献
• Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. Pubmed